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Background: Progressive accumulation of α-synuclein (α-Syn) protein in different brain regions is a hallmark of
synucleinopathic diseases, such as Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. α-
Syn transgenic mouse models have been developed to investigate the effects of α-Syn accumulation on behavioral
deficits and neuropathology. However, the onset and progression of pathology in α-Syn transgenic mice have not
been fully characterized. For this purpose we investigated the time course of behavioral deficits and
neuropathology in PDGF-β human wild type α-Syn transgenic mice (D-Line) between 3 and 12 months of age.
Results: These mice showed progressive impairment of motor coordination of the limbs that resulted in significant
differences compared to non-transgenic littermates at 9 and 12 months of age. Biochemical and
immunohistological analyses revealed constantly increasing levels of human α-Syn in different brain areas. Human
α-Syn was expressed particularly in somata and neurites of a subset of neocortical and limbic system neurons. Most
of these neurons showed immunoreactivity for phosphorylated human α-Syn confined to nuclei and perinuclear
cytoplasm. Analyses of the phenotype of α-Syn expressing cells revealed strong expression in dopaminergic
olfactory bulb neurons, subsets of GABAergic interneurons and glutamatergic principal cells throughout the
telencephalon. We also found human α-Syn expression in immature neurons of both the ventricular zone and the
rostral migratory stream, but not in the dentate gyrus.
Conclusion: The present study demonstrates that the PDGF-β α-Syn transgenic mouse model presents with early
and progressive accumulation of human α-Syn that is accompanied by motor deficits. This information is essential
for the design of therapeutical studies of synucleinopathies.
Keywords: Behavior, Immunofluorescence, Motor deficit, Mouse model, Parkinson’s disease, Phosphorylation,
Synucleinopathy, α-Synuclein, TransgeneBackground
Synucleinopathic diseases, like Parkinson’s disease (PD),
dementia with Lewy bodies (DLB) and multiple system
atrophy (MSA), are all characterized by a pathologic ag-
gregation of α-Synuclein (α-Syn) protein in distinct brain
regions (reviewed by [1]). Increased expression of α-Syn
can be caused by a dominant heritable form of PD due
to duplication or triplication of the α-Syn gene [2-4]. In* Correspondence: birgit.hutter-paier@qps.com
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reproduction in any medium, provided the ororder to model such synucleinopathies in vivo different
mouse models were developed that overexpress human
wild type α-Syn (hα-Syn) [5-12]. When expression is
driven by the murine Thy1 promoter, transgenic mice
accumulate wild type hα-Syn in cortical and subcortical
regions including the nigrostriatal system [6,13] whereas
under the human PDGF-β promoter hα-Syn accumu-
lates preferentially in the neocortex and limbic system
(D-Line) [5].
Abnormal accumulation of hα-Syn in D-Line trans-
genic mice is accompanied by alterations in mGluR5
and autophagy similar to what has been observed inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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over the behavioral and neurodegenerative pathology in
D-Line mice can be reversed with mGluR5 antagonists
[15] or by promoting the clearance of α-Syn with rapa-
mycin [14], Beclin 1 [16,17] and neurosin [18]. Given
the behavioral phenotype and the predominant accumu-
lation of α-Syn in the neocortex and limbic system, these
studies suggest that the PDGF-β hα-Syn transgenic
mouse model reproduces some aspects of synucleinopa-
thies such as DLB. Recent studies have tested com-
pounds developed to ameliorate PD-like pathology in
the D-Line mouse model and were able to show a reduc-
tion in the accumulation of α-Syn, total and oxidized
α-Syn levels and behavioral deficits [19-22].
Taken together, these results indicate that this trans-
genic model might be useful for studies of α-Syn target
validation. However, the progression of the behavioral def-
icits and pathology in D-Line mice has not been fully
characterized. For this purpose we investigated the time
course of behavioral deficits and neuropathology in D-
Line mice. The occurrence of motor deficits was investi-
gated using a challenging beam walk paradigm. We also
quantified hα-Syn expression in the hippocampus and stri-
atum using a biochemical approach. Moreover, by quanti-
tative immunofluorescence at different ages we comparedFigure 1 D-Line mice present impaired motor coordination. The numb
transgenic littermates were measured with the challenging beam walk test
SEM; t-test. When analyzed by one way or two way ANOVA followed by Bonf
observed. (A-C) D-Line male: n = 6; D-Line female: n = 6; wt male: n = 6; wt f
D-Line mice compared to non-transgenic littermates in 9 months old individu
D-Line (n = 8); ntg (n = 6). Graph shows mean ± SEM; Mann–Whitney U-test.expression levels of both murine α-Syn and hα-Syn in the
cortex, hippocampus, striatum and substantia nigra
relative to non-transgenic littermates. Furthermore, we
identified several cell populations that express transgenic
hα-Syn in different areas of the adult brain.Results
Progressive motor deficits of D-Line mice
Motor coordination, in particular of the hind limbs, and
balance of all mice was evaluated with the challenging
beam walk test at 6, 9 and 12 months of age to evaluate
progression of motor deficits in adult, mature and aging
mice. The time to cross the beam, the number of steps
and slips, and the ratio of slips per step was recorded.
No significant changes in the number of slips were
observed in 6 months old D-Line and control animals
(Figure 1A). 9 months old transgenic and non-transgenic
male mice made significantly more slips compared to the
corresponding female mice (Figure 1B). Transgenic female
mice of the same age performed significantly worse com-
pared to the corresponding female non-transgenic con-
trols as analyzed by t-test. The same trend was observed
in male mice, but the results were not statistically signifi-
cant (Figure 1B). The observed deficits faded at the age ofer of slips by male and female D-Line mice compared to non-
in 6 (A), 9 (B) and 12 (C) months old individuals. Graphs show mean ±
erroni’s post hoc test, factor transgene, no significant changes were
emale: n = 6. (D) Pooled data of either sex on nest building behavior of
als. Graph represents the mean nest building score (scoring from 1–5).
* p < 0.05; ** p < 0.01.
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female D-Line and non-transgenic mice remained
(Figure 1C). The significant differences shown in
Figure 1A-C were detected by analyzing data with t-test.
Analyses of the presented data for the factor gender by
two way ANOVA followed by Bonferroni’s post hoc test
revealed a significant influence of the gender for trans-
genic as well as non transgenic mice (p < 0.05, data not
shown). Analyses of data by two way ANOVA followed by
Bonferroni’s post hoc test for the factor transgene and by
one way ANOVA did not reveal any significances. Ana-
lysis of the number of slips for progressive changes over
age separated by sex showed only a significant improve-
ment of non-transgenic female mice over age (two way
ANOVA followed by Bonferroni’s post hoc test, factor
time; data not shown). The time and number of steps
required to traverse the beam and the ratio of slips
per step did not differ significantly between D-Line and
non-transgenic littermates (two way ANOVA, one-way
ANOVA and t-test). In order to verify that the observed
motor differences between the D-Line mice and non-
transgenic littermates were not caused by modifications of
spontaneous activity or deficits in spatial learning, the
cylinder test and the two-choice swim test were per-
formed, and no significant effects were detected (data not
shown). General health of each mouse was determined
using the Irwin test—including the wire hanging test and
vertical pole test, assessing physical characteristics and ab-
normalities, sensorimotor reflexes and motor abilities—
but no significant differences were observed. Overall, all
animals appeared healthy over the course of the study.
The nest building test was used to analyze D-Line mice
compared to non-transgenic littermates at 9 months of
age. D-Line mice showed a significantly reduced nest
building behavior (Figure 1D). While non-transgenic mice
built an almost perfect nest with the provided material,Figure 2 Increasing transgenic α-Synuclein protein levels in the brain
of hα-Syn in brain homogenates. Panels show hα-Syn expression levels of
striatum (B) and 6 months old non-transgenic littermates. D-Line mice: 3, 9
one animal were excluded by Grubb’s Outlier test. Striatum ntg value = 0.
analyses. Graphs show mean ± SEM; one-way ANOVA followed by Bonferrothe D-Line mice shredded only about 50% of the nesting
material and an easily identifiable nest site was missing.
Since no significant differences between male and female
D-Line mice were observed (data not shown), data of both
sexes were pooled for Figure 1D. Taken together, our
behavioral analysis argues for an impairment of motor
coordination in transgenic mice during execution of chal-
lenging tasks, whereas overall motor activity is largely
unaffected.
Quantification of α-synuclein protein levels over age
Analyses of hα-Syn protein levels by ELISA showed a
significant increase in the hippocampus at 12 months
of age compared to 3 and 6 months old D-Line mice
(Figure 2A). The increase was less pronounced in the stri-
atum but was significant at 12 months compared to 3 and
6 months (Figure 2B). In order to investigate whether the
progressive accumulation of hα-Syn in brain homogenates
using ELISA could also be detected in situ we next
analyzed expression levels of human and murine protein
isoforms in the cortex, hippocampus, striatum and sub-
stantia nigra by quantification of immunofluorescent
labeling using isoform-specific antibodies. In all analyzed
brain areas the pan (murine and human) α-Syn levels of
D-Line mice did not differ from non-transgenic litter-
mates, and in both genotypes the total protein levels did
not change significantly over age in cerebral cortical
(Figure 3A-B) and subcortical (Figure 4A-B) areas. How-
ever, analyses restricted to transgenic hα-Syn, the same
isoform that was analyzed biochemically by ELISA, showed
significantly higher immunofluorescence signal intensity
(p < 0.001) in D-line mice compared to ntg mice already at
3 months of age in cortical areas (Figure 3C-D). Expression
levels of hα-Syn in the striatum and the substantia nigra
were also above baseline in D-line mice (Figure 4C-D) but
were generally lower than in cortical areas. Despite theseof 3–12 months old D-Line mice. ELISA was used to analyze levels
3, 6, 9 and 12 months old D-Line mice in the hippocampus (A) and
and 12 months old (n = 6), 6 months (n = 5), ntg (n = 1). Values of
Data of the non-transgenic mouse were not included in statistical
ni’s post hoc test. * p < 0.05; ** p < 0.01.
Figure 3 Quantitative analyses of α-Synuclein levels in cerebral cortex of 3–12 months old mice. Immunofluorescence intensity of pan
α-Syn labeling (A, B) and transgenic hα-Syn labeling (C, D) in the cortex (left panels) and hippocampus (right panels). The expression levels of pan
α-Syn are constant throughout life and do not differ between genotypes, whereas hα-Syn expression in D-Line mice doubles between 3 and
12 months of age. D-Line: 3 months (n = 8), 6 months (n = 9), 9 months (n = 6), 12 months (n = 8); ntg mice: 3 months (n = 4), 6 months
(n = 4), 9 months (n = 5), 12 months (n = 3). Graphs show mean ± SEM; one-way ANOVA followed by Bonferroni’s post hoc test.
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significant increase of hα-Syn immunofluorescence could
be observed in all four brain areas of D-Line mice
(Figures 3C-D, 4C-D), consistent with the data obtained by
ELISA. This result, together with the absence of any age-
related change in pan α-Syn, raises the possibility that
adaptive mechanisms may downregulate murine α-Syn
expression to ensure homeostatically appropriate protein
levels throughout life. An alternative explanation for the
finding of constant pan α-Syn levels is that the pan-specific
monoclonal antibody may have lower affinity for the
human isoform compared to murine α-Syn. This could
potentially be assessed using an antibody that specifically
detects only murine α-Syn, but to our knowledge such a
reagent is not available.
Distribution pattern of human, murine and
phosphorylated α-synuclein protein
Next we investigated the distribution patterns of hα-Syn
and pan α-Syn isoforms by double-immunofluorescent
labeling throughout the brain (Figure 5A-B). High levels
of hα-Syn were detected in the pontine nucleus and in the
cortex, including the cortical part of the amygdala and the
hippocampus. High levels of hα-Syn accumulation were
also detected in the striatum, ventral hypothalamus and
in the olfactory bulb. Double-immunofluorescence forhα-Syn and a N-terminal epitope of both murine and
human α/β-synuclein (N-α/β-Syn) at higher magnification
revealed that transgenic hα-Syn obviously accumulates in
somata and proximal dendrites. This is also evident in
layers with few neuronal somata but high density of
neuropil (Figure 5C-D), suggesting subcellular targeting of
overexpressed hα-Syn to both dendrites and axons. In
contrast, N-α/β-Syn is preferentially expressed in synaptic
terminals, notably in the stratum lucidum of hippocampal
CA3 (Figure 5C,E) and less obvious in the neocortex
(Figure 5D, F), consistent with previous reports on largely
presynaptic expression in wild type mice [23,24].
Next, we investigated the expression pattern of phos-
phorylated protein (Figure 6) using an antibody specifically
directed against an epitope including the phosphorylated-
Serine 129 residue of the human α-Synuclein isoform
(pS129-hα-Syn). Phosphorylation at residues S87 and S129
is of particular interest for synucleinopathy research be-
cause it has been argued that phosphorylation at these
residues might modulate the formation of protein aggrega-
tions, e.g. inclusion bodies and fibrillary structures [25-27].
We found that in the hippocampus and neocortex, the sub-
cellular expression of phα-Syn is largely restricted to neur-
onal nuclei (Figure 6), as evident from the overlay with the
nuclear dye DAPI (Figure 6C). Qualitative analysis of
pS129-hα-Syn suggests that the vast majority of neuronal
Figure 4 Quantitative analyses of α-Synuclein levels in nigrostriatal areas of 3–12 months old mice. Immunofluorescence intensity of pan
α-Syn labeling (A, B) and transgenic hα-Syn labeling (C, D) in the dorsal striatum (left panels) and substantia nigra pars compacta (right panels).
The expression levels of pan α-Syn are relatively constant throughout life and do not differ between genotypes, whereas hα-Syn expression in
D-Line mice increases between 3 and 12 months of age. D-Line: 3 months (n = 8), 6 months (n = 9), 9 months (n = 6), 12 months (n = 8); ntg
mice: 3 months (n = 4), 6 months (n = 4), 9 months (n = 5), 12 months (n = 3). Graphs show mean ± SEM; one-way ANOVA followed by
Bonferroni’s post hoc test.
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able levels of pS129-hα-Syn. However, we found no
evidence for expression in synaptic terminals or patho-
logical intracellular accumulations in D-Line mice of up to
9 months. In contrast to the pS129S residue, phosphory-
lated S87 hα-Syn is undetectable in D-Line mice [27].
Identification of α-synuclein-expressing neurons
In order to identify neuronal populations that accumu-
late hα-Syn, several multichannel immunofluorescence
experiments were performed. Using antibodies against
GAD67 and tyrosine hydroxylase we found that hα-Syn
is expressed in subpopulations of GABAergic and dopa-
minergic neurons, respectively, of the olfactory bulb
(Figure 7A), and in GABAergic interneurons of cortical
areas (Figure 7B-C). Since some GABAergic somata
in the hippocampal formation show little or even no
GAD67 immunoreactivity [28] we alternatively identified
interneurons by expression of the neuregulin receptor
ErbB4 that is a selective marker for a subset of cortical
GABAergic neurons [29-31]. We detected hα-Syn in a
small number of ErbB4-positive interneurons in the
cornu ammonis and dentate gyrus but not on microglia
identified by Iba1 immunoreactivity (Figure 7D). Withregard to glutamatergic principal neurons, hα-Syn was not
detectable in mitral cells of the olfactory bulb (Figure 8A),
but strong expression was evident in subsets of neocortical
and hippocampal pyramidal cells (Figure 8B-C). We noted
the occurrence of strong hα-Syn immunoreactivity in some
regions of the adult brain featuring immature and mig-
rating neurons (Figure 9A-G), such as the ventricular zone
and the rostral migratory stream. Using multichannel
immunofluorescence, we confirmed hα-Syn expression in
immature migrating neurons that were identified by several
established markers such as doublecortin, PSA-NCAM
and ErbB4 ([32-36]. In contrast, hα-Syn immunoreactivity
was consistently absent from immature neurons in the
hippocampal dentate gyrus (Figure 9H), suggesting that
hα-Syn expression is not a unifying feature of migrating or
maturing neurons in adult D-Line mice. Taken together,
our data show that strong hα-Syn immunofluorescence
occurs region-specifically in heterogeneous populations of
neurons of the adult brain.
Discussion
This study was designed to characterize the time course
and progression of the pathology in D-Line mice, a
model of α-Syn accumulation similar to DLB. We found
Figure 5 Region-specific expression patterns of human α-Synuclein versus murine Synuclein in neocortical and hippocampal areas.
Coronal (A) and sagittal (B) overview images demonstrate that transgenic expression of hα-Syn (green channel) is most prominent in the cerebral
cortex (RSC, S1, Pir, CA1-3, M2, oCx), subcortical telencephalic structures (AMY, CPu, NAc, Olf), medial thalamic nuclei (mTh), the arcuate
hypothalamic nucleus (AHN), and the pontine nucleus (PN) in transgenic mice. Please note that expression in the hippocampal formation (HC) is
restricted to CA1-3 but is largely absent from dentate gyrus (DG) (A). In contrast, using antibodies directed against either (A) a species-
independent N-terminal epitope of N-α/β-Syn or (B) a species-independent epitope of pan α-Syn shows expression throughout most areas of the
brain including subcortical structures (red channel). Higher magnification reveals accumulation of transgenic hα-Syn in a subset of cells (arrows) in
the stratum pyramidale (sp) of hippocampal CA3 (C) and in cortical layers V-VI (D). Neuropil in strata oriens (so) and radiatum (sr) shows high hα-
Syn immunoreactivity, which in contrast is mostly absent arrowheads from strata lucidum (sl) and lacunosum moleculare (slm) (C). In non-
transgenic mice, hippocampal expression of murine α/β-Syn (E) is restricted to mossy fiber terminals in stratum lucidum (arrowheads) but is
absent from neuronal somata, whereas in the neocortex (F) some cells close to white matter (wm) are α/β-Syn positive arrows. Please note the
specificity of the antibody directed against the human isoform of α-Syn, as evident from absence of immunoreactivity on non-transgenic tissue
(green channel in E, F). Scale bar: 2 mm (A, B), 150 μm (C-F). Abbreviations: amygdala (AMY), cerebellum (Cb), cornu ammonis areas 1–3 (CA1-3),
caudate/putamen (CPu), motor cortex (M2), nucleus accumbens (NAc), orbital frontal cortex (oCx), olfactory bulb (Olf), piriform cortex (Pir),
retrosplenial cortex (RSC), somatosensory cortex (S1), thalamus (Th).
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of age complemented by alterations in the nest building
behavior. These deficits were accompanied by a parallel
age-dependent increase in the levels of hα-Syn in somata
and neuritic processes of a subset of neocortical, limbic
and nigrostriatal system cells. The mechanisms by which
accumulation of hα-Syn in these circuitries might result in
functional deficits are not completely clear. Recent findings
on changes in expression levels of neurotrophic factors
in hα-Syn transgenic mice [37] suggest that altered
BDNF levels could be linked to onset and progression of
Parkinson’s disease [38].
The progressive motor alterations in the challenging
beam walk test detected in D-Line mice are consistent
with previous studies using the rotarod and pole test[5,15] and support a dysfunction of the nigrostriatal
system. Also supporting this possibility, previous studies
have shown that D-Line mice of either sex generally
perform worse compared to non-transgenic littermates;
however, at the age of 9 months D-Line and non-
transgenic male mice consistently slip more often during
the challenging beam walk test than females. In transgenic
mice the sex difference seems to increase up to the age of
9 months, suggesting that hα-Syn has an earlier impact on
motor performance in male than in female mice. Interest-
ingly, these results are reminiscent of sex differences in
humans where female Parkinson patients show a delayed
onset of the disease compared to males [39].
Nest building behavior is an intrinsic behavior in both
female and male mice that requires proper fine motor
Figure 6 Phosphorylated human α-Synuclein is targeted to
nuclei but is undetectable in neurites. Immunoreactivity for
transgenic hα-Syn (green channel) is evident in a subset of pyramidal
neurons (A, C) in the hippocampal area CA3 and (B) in the
dorsolateral neocortex (arrowheads); in either area the transgenic
isoform is targeted to both somata and neurites. Using an antibody
against human protein phosphorylated at S129 (phα-Syn, red
channel), immunoreactivity is strong in most neurons that are
positive for hα-Syn but is spatially restricted to neuronal nuclei, as is
evident from co-localization with DAPI (arrowheads) (C). Scale bar:
150 μm (A, B), 100 μm (C). Abbreviations: cornu ammonis areas 1–3
(CA1-3), stratum oriens (so), stratum pyramidale (sp), stratum
lucidum (sl), stratum radiatum (sr), stratum lacunosum moleculare
(slm), white matter (wm), cortical layer V and VI (V and VI).
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perature and provides shelter during birth and rearing of
offspring. Different lesioning studies provide evidence that
nest building behavior strongly depends on the proper
function of the hippocampus, caudate putamen and ventral
mesencephalic tegmentum [40-42]. Moreover, nest building
was shown to be dopamine- and enkephalin-dependent
[43]. All these brain systems are known to be highly rele-
vant for PD [44,45], suggesting that the nest building test is
an appropriate tool for assessing Parkinson-associatedimpairments. Therefore, our here presented data of nest
building and motor deficits in the beam walk test suggest,
that D-Line transgenic mice represent with the most com-
mon behavioral symptoms of PD.
Analyses of hα-Syn levels in the brain by ELISA showed
an age dependent increase of transgenic protein levels in
the hippocampus and striatum between 3 and 12 months.
Using quantitative analysis of immunofluorescence against
hα-Syn we could verify this result in situ. Interestingly,
however, we detected neither genotype-dependent nor
age-dependent increases in total (human and murine) α-
Syn levels. Given that under the PDGF-β promoter the
mRNA expression of α-Syn is stable throughout life, the
progressive accumulation of hα-Syn protein in the brains
of the transgenic mice indicates deficits in clearance. This
is consistent with previous studies showing alterations in
the autophagy pathway in the D-
line mice [14,46], these alterations were reversed pharma-
cologically with rapamycin [14] or genetically with Beclin-
1 [17] or Atg7 [14] and worsen with shAtg7 [14] or
Bafilomycin-A1 [46]. In addition, the finding of constant
total α-Syn levels despite the parallel accumulation of
transgenic hα-Syn protein raises the possibility that the
expression of endogenous murine α-Syn might be a tightly
regulated mechanism. Overexpression of hα-Syn could
therefore be a trigger for homeostatic downregulation of
the murine isoform. Moreover, total α-Syn immunoreac-
tivity even decreased slightly in the substantia nigra of
non-transgenic animals suggesting that reduction of α-Syn
levels in the nigrostriatal dopaminergic pathway of older
mice is a normal event during aging in healthy rodents,
consistent with reports by other groups [47,48].
We identified subsets of transgene expressing neurons as
inhibitory GABAergic interneurons or excitatory glutama-
tergic pyramidal neurons in cortical areas. With respect to
dopaminergic cells, we found co-expression of hα-Syn and
tyrosine hydroxylase in many neurons of the olfactory bulb,
in contrast to the substantia nigra where only low levels of
hα-Syn were detectable. We also detected hα-Syn immu-
noreactivity in some GABAergic interneurons of the olfac-
tory bulb but, in contrast to cortical areas, not in
glutamatergic principal neurons (mitral cells). Overall, this
pattern is consistent with the reported expression of
PDGF-β in different types of neurons [49,50]. Our investi-
gation of hα-Syn phosphorylation at residue S129 shows
that immunoreactivity is largely restricted to the nuclei of
neurons that express high levels of the transgenic protein.
Of note, we found no indication of granular or fibrillary-
like accumulations of pS129-hα-Syn, opening the question
whether this nuclear immunoreactivity reflects regular
physiological events or rather indicates progression towards
neuropathology consistent with previous reports [51].
Finally, consistent with previous studies [52] we found that
hα-Syn accumulates in areas featuring immature neurons,
Figure 7 Region-specific expression of human α-Synuclein in different subpopulations of neurons. Triple immunofluorescent labeling
reveals expression of transgenic hα-Syn (green channel) in different types of neurons. (A) hα-Syn immunoreactivity is evident in a subset
(arrowheads) of dopaminergic neurons (TH, blue channel) in the glomerular layer (sgl), and occasionally (arrows) in GABAergic interneurons
(GAD67, red channel) throughout the olfactory bulb. (B) A subset of neocortical hα-Syn-positive neurons (arrows) are immunoreactive for the
interneuron marker GAD67 (red channel); however, this did not occur in the hippocampus (arrowheads) probably due to known low expression
levels of GAD67 in some types of interneurons (C). Using ErbB4 immunoreactivity as an alternative marker for GABAergic neurons, we found hα-
Syn expression in a subset of interneurons (arrows), but not in Iba1-immunoreactive microglia (arrowheads), in hippocampal area CA3 (D) and in
the dentate gyrus (E). Abbreviations: dentate gyrus (DG), glutamic acid decarboxylase 67 kD (GAD67), tyrosine hydroxylase (TH), stratum
plexiforme externum (spe), stratum oriens (so), stratum pyramidale (sp), stratum radiatum (sr), stratum moleculare (sm), stratum granulosum (sg),
hilus (hi) cortical layer V and VI (V and VI), cornu ammonis area 1/3 (CA1/3). Scale bar = 50 μm.
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Figure 8 Expression of human α-Synuclein in populations of principal neurons. Triple fluorescent labeling reveals that immunoreactivity of
both hα-Syn (green channel) and pan α-Syn (blue channel) is absent from neurogranin-positive mitral cells (NG, red channel) in the olfactory bulb
(arrowheads in A). In contrast, a subset of neocortical (B) and hippocampal (C) pyramidal neurons expresses α-Syn; co-localization of all three
color channels (arrows) is indicated by the occurrence of whitish pixels. Single channel images are rotated clockwise in panels A and C.
Abbreviations: neurogranin (NG), stratum plexiforme externum/internum (spe/i), stratum mitrale (smt), stratum oriens (so), stratum pyramidale (sp),
stratum radiatum (sr), cortical layers III and IV (III and IV), cornu ammonis area 3 (CA3). Scale bar = 50 μm.
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stream. Accumulation of hα-Syn in these areas results in
reduced proliferation and survival of neuroblasts [52],
however, the functional relevance of these alterations
is yet unknown. Interestingly, we found no indication of
hα-Syn immunoreactivity in maturing neurons of the
dentate gyrus, indicating that hα-Syn expression is not a
common feature of all populations of immature or
migrating neurons. Additional studies are required to inves-
tigate whether these regional differences have functional
relevance that may affect survival rates or maturation of
these cells.
Conclusions
Our data suggest that hα-Syn accumulates in subsets of
glutamatergic, dopaminergic, and GABAergic, neuronal
populations in the neocortex, limbic system and nigrostria-
tal system similar to the distribution of hα-Syn in DLB.
Immunoreactivity for human protein phosphorylated at
residue S129 is restricted to neuronal somata, whereasmuch of the additional immunofluorescent signal from hα-
Syn protein not phosphorylated at the S129 residue comes
from areas with few neuronal somata but dense neuropil,
thus mimicking the distribution of the endogenous murine
α-Syn isoform. We also detected progressively increasing
levels of hα-Syn protein during adulthood using different
experimental approaches, and concomitant impairment of
motor coordination. In contrast, the level of total α-Syn is
constant between 3–12 months, possibly due to a compen-
satory downregulation of the endogenous α-Syn isoform.
We conclude that different readouts, i.e. behavioral, bio-
chemical and histological, can detect structural and func-
tional pathology in the D-Line mouse model, and that this




For this study we used male and female mice over-
expressing human wild type α-Syn under the regulatory
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promoter with a C57BL/6xDBA background (D-Line,
[5]). All experiments were performed with hemizygous
D-Line mice and corresponding non-transgenic litter-
mates. Animals were housed in individually ventilated
cages on standardized rodent bedding (RettenmayerW).Figure 9 (See legend on next page.)The room temperature was kept at approximately 24°C and
the relative humidity between 40-70%. Mice were housed
under constant light-cycle (12 hours light/dark). Dried pel-
leted standard rodent chow (AltrominW) and normal tap
water were available to the animals ad libitum. The health
and well-being of each individual animal was monitored
(See figure on previous page.)
Figure 9 Human α-Synuclein is strongly expressed in immature neurons in a region-specific pattern. Immunofluorescent labeling of
hα-Syn (green channel) in different regions of the brain shows strong expression of transgenic α-Syn (arrowheads) in immature neurons in the
rostral migratory stream (RMS) (A, D, G) and in the ventricular zone (VZ) (B, C, E, F). We found no coexpression with either GAD67 or TH (A, B,
C), whereas many hα-Syn-positive cells were immunoreactive for doublecortin (DCX) in the RMS (D) and the VZ (E), indicating that hα-Syn is
expressed in subpopulations of immature migrating neurons. (F) We also found co-expression of hα-Syn and ErbB4 in the VZ (open arrowhead in
F) and the RMS (G), whereas hα-Syn was not expressed in microglia immunoreactive for Iba1 (arrow in F). The VZ and the RMS were identified by
immunoreactivity for DCX, ErbB4, or PSA-NCAM (G). (H) In contrast to the VZ and RMS, we found no indication for expression of either hα-Syn
(arrowhead) or ErbB4 (open arrowhead) in DCX-positive immature neurons (arrow) in the subgranular layer (sgl) of the hippocampal dentate
gyrus (DG). Single channel images are rotated clockwise in panel H. Abbreviations: caudate/putamen (CPu), corpus callosum (cc), glutamic acid
decarboxylase 67 kD (GAD67), hilus (hi), lateral ventricle (lv), olfactory bulb (Olf), stratum granulosum (sg), stratum moleculare (sm), tyrosine
hydroxylase (TH), doublecortin (DCX). Scale bar = 50 μm (A-E, H), 70 μm (F, G).
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lines for the care and use of laboratory animals and were
approved by the Styrian Government, Austria.
Behavioral tests
For behavioral tests 6, 9 and 12 months old animals were
used. 12 males (6 tg and 6 ntg) and 12 females (6 tg and 6
ntg) were analyzed per age group. The challenging beam
walk test was carried out with all mice as previously
described [53]. In short, mice were trained to traverse the
length of a beam starting at the widest section and ending
at the narrowest, most difficult section. The narrow end of
the beam led directly into the animal’s home cage. Mice
received two days of training before testing. In order to
increase difficulty on the day of testing, a wire mesh of
corresponding width was placed over the beam. On the
testing day mice were required to run five trials. Mice
were video-taped while traversing the grid-surfaced beam.
Videotapes were viewed and rated in slow motion for
slips, number of steps, slips per step and time to traverse.
After normal distribution was verified by Kolmogorov-
Smirnov test, group differences were calculated by one-
way ANOVA, two-way ANOVA followed by Bonferroni’s
post hoc test, factors transgene, gender and time, and
unpaired t-test, using GraphPad Prism 4.03.Table 1 List of primary antibodies
Species Antigen Clone Source
rat Human α-Synuclein 15 G7 Enzo Life
mouse Human phospho α-Synuclein EP1536Y Abcam, C
mouse α-Synuclein 4D6 Abcam
goat α/β-Synuclein, N-terminal poly Santa Cru
goat Doublecortin poly Santa Cru
rabbit Iba1/AIF1 poly ProteinTe
rabbit Tyrosine hydroxylase poly Novus Bi
rabbit Neurogranin poly Millipore,
mouse GAD67 1 G10.2 Millipore
mouse PSA-NCAM 2-2B Millipore
mouse N-ErbB4 H4.77.16 LabVision
rabbit C-ErbB4 mAb-10 BuonannTo test the individual nest building behavior, 9 months
old mice were housed separately overnight in cages con-
taining wood chip bedding and one 5 cm square piece of
pressed cotton (nestlet). No other nesting material was
provided. The nestlet was introduced on the day before
the evaluation of the nest. The following morning the
nest was assessed, according to a five-point scale [54]. If
the nestlet was not noticeably touched it was scored
with 1 point. A near perfect nest, in which at least 90%
of the nestlet was used, was scored with 5 points. After
normal distribution was unconfirmed by Kolmogorov-
Smirnov test, group differences were calculated by
Mann–Whitney U-test, using GraphPad Prism 4.03.
Tissue preparation
Mice were deeply anesthetized by Isoflurane (BAXTERW,
Austria) and the thorax was opened to excavate the heart.
Animals were flush-perfused transcardially with 0.9%
saline through the left ventricle. The hemispheres were
divided at midline. The right hemisphere was immersion
fixed in 4% paraformaldehyde in 0.1 M phosphate buffer,
pH 7.4, for 1 h at room temperature (RT), cryoprotected
in 30% sucrose, and snap-frozen in dry ice-cooled isopen-
tane for further histological evaluations. The left hemi-
sphere was dissected into hippocampus, striatum and restItem # Dilution
Sciences, Plymouth Meeting, PA 804-258-L001 1:20
ambridge, UK ab51253 1:2000
ab1903 1:500
z Biotechnology, Santa Cruz, CA sc-7012 1:300
z Biotechnology sc-8066 1:200
ch Group, Chicago, IL 10904-1-AP 1:500
ologicals, Cambridge, UK NB300-109 1:1000
Temecula, CA AB5620 1:1000
MAB5406 1:2000
MAB5324 1:200
, Fremont, CA MS-270 (mAb-77) 3 μg/ml
o Lab, NIH; Vullhorst et al., 2009 mAb-10 3 μg/ml
Amschl et al. BMC Neuroscience 2013, 14:6 Page 12 of 14
http://www.biomedcentral.com/1471-2202/14/6brain, shock-frozen on dry ice, and stored at −80°C for
biochemical hα-Syn determination.
Biochemistry
We analyzed expression levels of hα-Syn in the hippocam-
pus and striatum of D-Line mice and non-transgenic
littermates at different ages: D-Line: 3, 9 and 12 months
(n = 6), 6 months (n = 5); ntg: 6 months (n = 1). Total pro-
tein was extracted from brain samples by homogenization
in 8 volumes guanidine buffer (5 M guanidine HCl,
50 mmol/L TrisHCl, pH 8.0). The homogenates were
mixed for 4 h at RT. Samples were then diluted 500x
(hippocampus), 100x (striatum) with cold reaction buffer
(2.68 mmol/L KCl, 1.47 mmol/L KH2PO4, 136.89 mmol/L
NaCl, 8.1 mmol/L Na2HPO4, 5% BSA, 0.03% Tween-20
and protease inhibitor cocktail) and centrifuged at 16.000 g
for 20 min at 4°C. Supernatants were analyzed for total hα-
Syn concentrations by ELISA (Hu α-Synuclein ELISA Kit
#KHB0061, Invitrogen) following the manufacturer’s pro-
tocol. Group differences were statistically analyzed by
excluding outliers using Grubb’s test and subsequent one-
way ANOVA followed by Bonferroni’s post hoc test, using
GraphPad Prism 4.03.
Histology
We quantitatively investigated tissue obtained from mice
at different ages (Figures 3–4). D-Line / ntg: 3 months
(n = 8 / 4); 6 months (n = 9 / 4); 9 months (n = 6 / 5);
12 months (n = 8 / 3). A natural α-Syn knockout line
from Harlan (C57BL/6JOlaHsd) served as negative con-
trol to test for antibody specificity (Additional file 1).
Qualitative multichannel immunofluorescence experi-
ments (Figures 5–9) were performed at RT on sagittal
cryosections (10 μm thick; systematic uniform random
sampling) of adult mice (age 9 months, n = 3 per geno-
type, mixed sex) using the following protocol: Wash cryo-
sections 2 × 5 min in 0.05 M tris-buffered saline (TBS,
pH 7.6) with 0.25% Triton X-100, block 1 h with MOM
blocking reagent (Vector, Burlingame, CA), wash
2 × 2 min, incubate 5 min in MOM diluent, incubate 40 h
at 4°C in new MOM diluent with primary antibodies,
wash 3 × 5 min, incubate secondary antibodies 1 h in
MOM diluent wash 3 × 5 min, mount with Mowiol.
The expression of transgenic hα-Syn was detected with a
rat monoclonal antibody (clone 15 G7) directed against
residues 116–131 near the C-terminus of hα-Syn; this anti-
body does not bind to murine α-Syn. hα-Syn phosphory-
lated at Serine 129 (pS129-hα-Syn) was visualized with a
rabbit monoclonal antibody (clone EP1536Y). We detected
α/β-Synuclein expression using a goat polyclonal antibody
raised against an N-terminal sequence of α-Syn of human
origin (N-α/β-Syn); this antibody labels both murine and
human isoforms of α/β-Syn. A pan-specific (pan α-Syn)
mouse monoclonal antibody (clone 4D6) was used todetect both murine α-Syn and hα-Syn. Primary anti-α-Syn
antibodies were tested for specificity on brain sections of
α-Syn knockout mice as shown in a supplementary figure
(Additional file 1). Detailed information on all primary
antibodies used in this study is provided in Table 1.
Secondary antibodies donkey anti-rat, donkey anti-
mouse, donkey anti-rabbit, and donkey anti-goat were
labeled with Cy2/DyLight488, Cy3, or Cy5/DyLight649
fluorophores (Jackson ImmunoResearch, West Grove,
PA); all secondary antibodies were highly cross-adsorbed
(ML quality) to prevent unspecific cross-reactivity. Spe-
cificity of secondary antibodies was assessed by omitting
primary antibodies on parallel section as shown in an
additional file (Additional file 1). Controls were routinely
executed together with regular experiments.
Images for quantitative analysis were recorded with an
Axio mRm camera mounted on AxioImager Z1 epifluor-
escence microscope at 10x magnification. Exposure time
and additional settings were kept constant for all images
used in quantification. Camera was set to the linear
default. Regions of interest (ROI) were defined by individ-
ual delineation of the cortex, hippocampus and substantia
nigra, and total α-Syn immunofluorescence signal was
determined by integrating pixel intensity throughout the
ROI using ImageProPlus Software (Version 6.2). Five
sections per brain region were analyzed deriving from five
different systematically chosen medio-lateral levels. After
normal distribution was verified by Kolmogorov-Smirnov
test, group differences in histological variables were calcu-
lated by one-way ANOVA followed by Bonferroni’s post
hoc test, using GraphPad Prism 4.03. Epifluorescence
z-stack images (8–10 z-levels, 0.3 μm apart, 20% overlay)
presented in the figures were obtained at 40x magnifica-
tion and were collapsed using the Extended Focus function
in AxioVision (v4.8) software.Additional file
Additional file 1: Negative controls for specificity of primary and
secondary antibodies. Specificity of (A) the monoclonal rat anti-human α-
Syn antibody and (B) the pan-specific monoclonal mouse anti-human and
anti-murine α-Syn antibody were tested on frontal sections through the
neocortex (Cx), corpus callosum (cc) and caudate/putamen (CPu) of α-Syn
knockout mice. We also tested specificity of secondary antibodies (C-E) on
sections through the hippocampal formation of D-Line mice; the panels
show residual fluorescence in the CA3 region after omitting primary
antibodies. Only low level background fluorescent signal was detected in all
control experiments. Abbreviations: stratum oriens (so), stratum pyramidale
(sp), stratum radiatum (sr). Scale bar = 70 μm (A, B), 50 μm (C-E).Abbreviations
(hα-Syn): Human α-synuclein; (DLB): dementia with Lewy bodies;
(DCX): doublecortin; (ErbB4): v-erb-a erythroblastic leukemia viral oncogene
homolog 4; (GAD67): glutamic acid decarboxylase 67 kD; (Iba1/AIF1): ionized
calcium binding adaptor molecule 1/allograft inflammatory factor 1;
(MSA): multiple system atrophy; (ntg): non-transgenic; (PD): Parkinson’s
disease; (phα-Syn): phospho-S129 human α-synuclein; (PSA-NCAM): polysialic
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http://www.biomedcentral.com/1471-2202/14/6acid-neuronal cell adhesion molecule; (ROI): region of interest; (TH): tyrosine
hydroxylase.
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